Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Borken – page 61

1 431 clinical trials in Borken, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Borken at a glance
1 431
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 431 trials in Borken

Open in trial search

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Study of AMG 193 tablets for patients with advanced non-small cell lung cancer (NSCLC) who have previously received treatment and have MTAP gene deletion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Study on the Effects and Safety of Ginkgo Biloba Extract in Patients with Cognitive Impairment After COVID-19

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M)
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Gastric cancer+1

Not recruiting

Study on the Effectiveness and Safety of AZD0901 Compared to Standard Treatments for Adults with Advanced Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Neurodermatitis

Not recruiting

Study on the Effects of Barzolvolimab for Patients with Prurigo Nodularis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Borken

What the registry says about research in the country

01 Neuropathic Pain Research

Investigating innovative treatments for patients with diabetic polyneuropathy, focusing on new therapeutic approaches for chronic pain management.

  • Diabetic Neuropathy
  • Pain Management
  • Treatment Efficacy

Clinical evaluations of add-on treatments aim to improve quality of life for patients with chronic neuropathic conditions.

02 Trauma-Related Neuropathy

Studies examining treatment options for post-operative and traumatic peripheral neuropathy, with emphasis on chronic pain relief strategies.

  • Post-Surgical Pain
  • Trauma-Induced Neuropathy
  • Pain Relief Solutions

Research focused on developing effective therapeutic interventions for trauma-related chronic pain conditions.

03 Central Neuropathy Studies

Comprehensive research into central neuropathy of various origins, evaluating novel treatment approaches for chronic pain management.

  • Central Nervous System
  • Pain Treatment
  • Therapeutic Efficacy

Advanced clinical trials exploring innovative solutions for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigation of new therapeutic approaches for managing chronic back pain, focusing on treatment tolerability and effectiveness.

  • Back Pain Management
  • Pain Relief
  • Treatment Outcomes

Studies aimed at improving treatment options for patients suffering from persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.